Presentation is loading. Please wait.

Presentation is loading. Please wait.

Treatment effect of sublingual immunotherapy tablets and pharmacotherapies for seasonal and perennial allergic rhinitis: Pooled analyses  Stephen R. Durham,

Similar presentations


Presentation on theme: "Treatment effect of sublingual immunotherapy tablets and pharmacotherapies for seasonal and perennial allergic rhinitis: Pooled analyses  Stephen R. Durham,"— Presentation transcript:

1 Treatment effect of sublingual immunotherapy tablets and pharmacotherapies for seasonal and perennial allergic rhinitis: Pooled analyses  Stephen R. Durham, MD, Peter S. Creticos, MD, Harold S. Nelson, MD, Ziliang Li, PhD, Amarjot Kaur, PhD, Eli O. Meltzer, MD, Hendrik Nolte, MD, PhD  Journal of Allergy and Clinical Immunology  Volume 138, Issue 4, Pages e4 (October 2016) DOI: /j.jaci Copyright © 2016 American Academy of Allergy, Asthma & Immunology Terms and Conditions

2 Fig 1 TNSS improvements with timothy grass and ragweed SLIT-tablets relative to placebo for SAR. *Calculated as follows: ([Active treatment − Placebo]/Placebo) × 100%. †Relative percentage improvement in rhinoconjunctivitis daily rescue medication score ranged from 27% to 38% in the trials. ‡Relative percentage improvement in rhinoconjunctivitis daily rescue medication score was 38% and 46% in the 2 trials. FE, Fixed effects. Journal of Allergy and Clinical Immunology  , e4DOI: ( /j.jaci ) Copyright © 2016 American Academy of Allergy, Asthma & Immunology Terms and Conditions

3 Fig 2 TNSS improvements with montelukast relative to placebo for SAR and PAR. *Calculated as follows: ([Active treatment − Placebo]/Placebo) × 100%. FE, Fixed effects. Journal of Allergy and Clinical Immunology  , e4DOI: ( /j.jaci ) Copyright © 2016 American Academy of Allergy, Asthma & Immunology Terms and Conditions

4 Fig 3 TNSS improvements with desloratadine relative to placebo for SAR and PAR. *Calculated as follows: ([Active treatment − Placebo]/Placebo) × 100%. †Trial allowed decongestant use. FE, Fixed effects. Journal of Allergy and Clinical Immunology  , e4DOI: ( /j.jaci ) Copyright © 2016 American Academy of Allergy, Asthma & Immunology Terms and Conditions

5 Fig 4 TNSS improvements with MFNS relative to placebo for SAR and PAR. *Calculated as follows: ([Active treatment − Placebo]/Placebo) × 100%. †Trial allowed antihistamine use. FE, Fixed effects. Journal of Allergy and Clinical Immunology  , e4DOI: ( /j.jaci ) Copyright © 2016 American Academy of Allergy, Asthma & Immunology Terms and Conditions

6 Fig 5 TNSS improvements with HDM SLIT-tablets relative to placebo for PAR. *Calculated as follows: ([Active treatment − Placebo]/Placebo) × 100%. †Relative percentage improvement in rhinitis daily rescue medication score in the 2 trials was 18% and 21%. FE, Fixed effects. Journal of Allergy and Clinical Immunology  , e4DOI: ( /j.jaci ) Copyright © 2016 American Academy of Allergy, Asthma & Immunology Terms and Conditions


Download ppt "Treatment effect of sublingual immunotherapy tablets and pharmacotherapies for seasonal and perennial allergic rhinitis: Pooled analyses  Stephen R. Durham,"

Similar presentations


Ads by Google